Scioderm, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sderm.com
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Scioderm, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT02670330
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Phase 3
Completed
- Conditions
- Epidermolysis Bullosa
- Interventions
- Drug: Placebo (SD-101-0.0) cream
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Scioderm, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT02384460
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Phase 2
Terminated
- Conditions
- Epidermolysis Bullosa
- Interventions
- Drug: SD-101 dermal cream (6%)
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Scioderm, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02090283
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
Phase 2
Completed
- Conditions
- Epidermolysis Bullosa
- Interventions
- Drug: SD-101 Dermal Cream (6%)Drug: SD-101 dermal cream (3%)Drug: Vehicle (SD-101 0%)
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Scioderm, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02014376
© Copyright 2025. All Rights Reserved by MedPath